Filtered By:
Source: International Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 388 results found since Jan 2013.
Temporal trends of atrial fibrillation and/or rheumatic heart disease-related ischemic stroke, and anticoagulant use in Chinese population: An 8-year study
Underuse of anticoagulants in ischemic stroke patients with atrial fibrillation (AF) and/or rheumatic heart disease (RHD) is a global concern, especially in China. However, the extent to which anticoagulants are underused in AF and/or RHD-related ischemic stroke in China has not been well characterized. We aimed to explore the temporal trends of AF and/or RHD-related ischemic stroke patients, anticoagulation use and factors related to suboptimal use of anticoagulants in a Chinese population.
Source: International Journal of Cardiology - August 15, 2020 Category: Cardiology Authors: Junfeng Liu, Yanan Wang, Wen Guo, Yajun Cheng, Shihong Zhang, Bo Wu, Ming Liu Source Type: research
The hospitalizations in hypertrophic cardiomyopathy: “the dark side of the moon”.
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - August 14, 2020 Category: Cardiology Authors: Emanuele Monda, Giuseppe Limongelli Tags: Editorial Source Type: research
The hospitalizations in hypertrophic cardiomyopathy: “The dark side of the moon”
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - August 14, 2020 Category: Cardiology Authors: Emanuele Monda, Giuseppe Limongelli Tags: Editorial Source Type: research
Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke
To determine association of discharge antiplatelet therapy prescription with 1-year outcomes among patients with AF admitted with acute ischemic stroke and discharged without oral anticoagulation.
Source: International Journal of Cardiology - August 13, 2020 Category: Cardiology Authors: Kay-Won Chang, Ying Xian, Xin Zhao, Xiaojuan Mi, Roland Matsouaka, Lee H. Schwamm, Shreyansh Shah, Barbara L. Lytle, Eric E. Smith, Deepak L. Bhatt, Gregg C. Fonarow, Jonathan C. Hsu Source Type: research
Circulating interleukins, coronary artery disease, ischemic stroke and atrial fibrillation: Connecting the dots between inflammation and cardiovascular disease
Cardiovascular disease (CVD) is the most prevalent disease in Western countries and causes poor quality of life, substantial health-care resource utilisation, and premature mortality. In the last decades, many CV risk factors have been identified and addressed accordingly [1]. However, a large proportion of cardiovascular events remain unexplained by current risk scores based on the levels of traditional cardiovascular risk factors, suggesting that other important pathways might be involved in the initiation and evolution of atherosclerosis and its complications.
Source: International Journal of Cardiology - April 20, 2020 Category: Cardiology Authors: Nicola Riccardo Pugliese, Stefano Masi Tags: Editorial Source Type: research
Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: A two sample Mendelian randomization
The causal role of interleukins (ILs) for cardiovascular disease has not been fully elucidated. We conducted a Mendelian randomization study to investigate the associations of circulating ILs with coronary artery disease (CAD), atrial fibrillation (AF), and ischemic stroke.
Source: International Journal of Cardiology - March 20, 2020 Category: Cardiology Authors: Shuai Yuan, Ang Lin, Qiqiang He, Stephen Burgess, Susanna C. Larsson Source Type: research
Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial
Diabetes mellitus is an independent risk factor for stroke and atrial fibrillation. Therefore, the risk/benefit profile of the oral factor Xa inhibitor edoxaban stratified by diabetes is of clinical interest.
Source: International Journal of Cardiology - January 29, 2020 Category: Cardiology Authors: Anna Plitt, Christian T. Ruff, Assen Goudev, Joao Morais, Miodrag C. Ostojic, Michael A. Grosso, Hans J. Lanz, Jeong-Gun Park, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano Source Type: research
The association between pulmonary hypertension and stroke: a systematic review and meta-analysis
We thank Wang et al. for their comments and for bringing forward the challenges in managing care of patients with pulmonary hypertension (PH) and stroke. We acknowledge multiple possible mechanisms of stroke in patients with PH, and we highlighted them in our work, including paradoxical emboli and atrial fibrillation [1]. However, polycythemia (increased red cells) or other myeloproliferative disorders are considered to be a cause and not a consequence of PH [2,3]. In mice models, Sala et al. have showed that chronic hypoxia could lead to both PH and polycythemia [4].
Source: International Journal of Cardiology - December 11, 2019 Category: Cardiology Authors: Trushil G. Shah, Jaini M. Sutaria, Manav V. Vyas Tags: Letter to the Editor Source Type: research
In reply: Stroke in pulmonary hypertension: Is it predictable or preventable?
We thank Wang et al. for their comments and for bringing forward the challenges in managing care of patients with pulmonary hypertension (PH) and stroke. We acknowledge multiple possible mechanisms of stroke in patients with PH, and we highlighted them in our work, including paradoxical emboli and atrial fibrillation [1]. However, polycythemia (increased red cells) or other myeloproliferative disorders are considered to be a cause and not a consequence of PH [2,3]. In mice models, Sala et al. have showed that chronic hypoxia could lead to both PH and polycythemia [4].
Source: International Journal of Cardiology - December 11, 2019 Category: Cardiology Authors: Trushil G. Shah, Jaini M. Sutaria, Manav V. Vyas Tags: Letter to the Editor Source Type: research
NOACs in adult congenital heart disease – Still limited experience
With advances in congenital heart disease treatment, more patients with repaired or palliated defects are living longer [1]. Adult congenital heart disease (ACHD) is also associated with an increased risk of atrial fibrillation [2] and stroke, both haemorrhagic and embolic [3,4]. While there is an abundance of clinical trials evaluating novel oral anticoagulants, NOACs, in patients with acquired heart disease the opposite is true for ACHD. In the current issue, Pujol and co-workers [5] report their single centre experience of 215 ACHD patients treated with NOACs.
Source: International Journal of Cardiology - November 18, 2019 Category: Cardiology Authors: Mikael Dellborg, Zacharias Mandalenakis Tags: Editorial Source Type: research
One for all and all for one? The dilemma of optimal management of atrial fibrillation with cardiac co-morbidities
Patients with non-valvular atrial fibrillation (AF) and concomitant heart failure or coronary artery disease (CAD) are at particularly high risk of thromboembolic complications, requiring careful stroke prevention management. The development of the direct oral anticoagulants has undoubtedly improved secondary prevention of stroke arising from venous sources, while antiplatelet therapy is an essential mainstay of secondary prevention in patients with CAD. The combination, however, is associated with an increased risk of major bleeds, so the decision whether to continue with antiplatelet treatment on top of life-long anticoa...
Source: International Journal of Cardiology - October 6, 2019 Category: Cardiology Authors: Anke C. Fender, Dobromir Dobrev Source Type: research
The association between pulmonary hypertension and stroke: A systematic review and meta-analysis
Pulmonary hypertension is associated with atrial fibrillation and paradoxical embolism. Yet, the association between pulmonary hypertension and stroke has not been well studied.
Source: International Journal of Cardiology - July 30, 2019 Category: Cardiology Authors: Trushil G. Shah, Jaini M. Sutaria, Manav V. Vyas Tags: Short communication Source Type: research
Stroke risk assessment in atrial fibrillation: Beyond atrial rhythm
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is responsible for at least 20% of all strokes. Moreover, strokes associated to AF are largely avoidable, as the use of anti-vitamin K drugs can prevent>65% of all strokes, and direct oral anticoagulants con reduce the rate of stroke by a further 19% [1].
Source: International Journal of Cardiology - May 22, 2019 Category: Cardiology Authors: Giovanni Luca Botto, Francesco Maria Brasca Tags: Editorial Source Type: research
Real-world persistence with direct oral anticoagulants (DOACs) in na ïve patients with non-valvular atrial fibrillation
Anticoagulation therapy is central for the management of stroke in patients with non-valvular atrial fibrillation (NVAF). Persistence with oral anticoagulation is essential to prevent thromboembolic complications.
Source: International Journal of Cardiology - April 18, 2019 Category: Cardiology Authors: Eliana Ferroni, Nicola Gennaro, Giorgio Costa, Ugo Fedeli, Gentian Denas, Vittorio Pengo, Maria Chiara Corti Source Type: research
Atrial fibrillation case finding in over 65 s with cardiovascular risk factors – Results of initial Scottish clinical experience
Atrial fibrillation (AF) is a major preventable risk factor for stroke and may be silent in elderly individuals who are at especially high risk. This paper describes the first phase of implementation of a clinical AF detection programme in a community setting. Objectives were (i) to determine the feasibility of using a handheld ECG recording system for AF detection among individuals aged 65 years or more, who have cardiovascular risk factors. (ii) to estimate the yield of previously undiagnosed atrial fibrillation cases, and the proportion of these who would be suitable for oral anticoagulation.
Source: International Journal of Cardiology - March 28, 2019 Category: Cardiology Authors: Neil R. Grubb, Douglas Elder, Paul Broadhurst, Anne Reoch, Emma Tassie, Neilson Aileen Source Type: research
